These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27155597)

  • 1. Assessing the predictive value of the rodent neurofunctional assessment for commonly reported adverse events in phase I clinical trials.
    Mead AN; Amouzadeh HR; Chapman K; Ewart L; Giarola A; Jackson SJ; Jarvis P; Jordaan P; Redfern W; Traebert M; Valentin JP; Vargas HM
    Regul Toxicol Pharmacol; 2016 Oct; 80():348-57. PubMed ID: 27155597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The standardized functional observational battery: Its intrinsic value remains in the instrument of measure: The rat.
    Gauvin DV; Yoder JD; Holdsworth DL; Harter ML; May JR; Cotey N; Dalton JA; Baird TJ
    J Pharmacol Toxicol Methods; 2016; 82():90-108. PubMed ID: 27534836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative equivalence of CNS safety (FOB) assessment outcomes in male and female Wistar-Han and Sprague-Dawley rats.
    Gauvin DV; Dalton JA; Harter ML; Holdsworth D; May J; Tapp R; Zimmermann ZJ; Kilgus Q; Baird TJ
    J Pharmacol Toxicol Methods; 2019; 95():2-11. PubMed ID: 30476622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The functional observational battery and modified Irwin test as global neurobehavioral assessments in the rat: Pharmacological validation data and a comparison of methods.
    Redfern WS; Dymond A; Strang I; Storey S; Grant C; Marks L; Barnard C; Heys C; Moyser K; Greenwood K; Cobey D; Moore N; Karp NA; Prior H
    J Pharmacol Toxicol Methods; 2019; 98():106591. PubMed ID: 31146025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofunctional test batteries in safety pharmacology - Current and emerging considerations for the drug development process.
    Jackson SJ; Authier S; Brohmann H; Goody SMG; Jones D; Prior H; Rosch A; Traebert M; Tse K; Valentin JP; Milne A
    J Pharmacol Toxicol Methods; 2019; 100():106602. PubMed ID: 31238094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CNS Adverse Effects: From Functional Observation Battery/Irwin Tests to Electrophysiology.
    Fonck C; Easter A; Pietras MR; Bialecki RA
    Handb Exp Pharmacol; 2015; 229():83-113. PubMed ID: 26091637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Irwin Test and Functional Observational Battery (FOB) for Assessing the Effects of Compounds on Behavior, Physiology, and Safety Pharmacology in Rodents.
    Mathiasen JR; Moser VC
    Curr Protoc Pharmacol; 2018 Dec; 83(1):e43. PubMed ID: 30179315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety pharmacology investigations on the nervous system: An industry survey.
    Authier S; Arezzo J; Delatte MS; Kallman MJ; Markgraf C; Paquette D; Pugsley MK; Ratcliffe S; Redfern WS; Stevens J; Valentin JP; Vargas HM; Curtis MJ
    J Pharmacol Toxicol Methods; 2016; 81():37-46. PubMed ID: 27263834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a botanical composition, UP446, on respiratory, cardiovascular and central nervous systems in beagle dogs and rats.
    Yimam M; Lee YC; Jia Q
    Regul Toxicol Pharmacol; 2016 Jun; 77():184-91. PubMed ID: 27012374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events of fluoroquinolones vs. other antimicrobials prescribed in primary care: A systematic review and meta-analysis of randomized controlled trials.
    Tandan M; Cormican M; Vellinga A
    Int J Antimicrob Agents; 2018 Nov; 52(5):529-540. PubMed ID: 29702230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOB vs modified Irwin: What are we doing?
    Gauvin DV; Zimmermann ZJ
    J Pharmacol Toxicol Methods; 2019; 97():24-28. PubMed ID: 30885703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An optimised methodology for the neurobehavioural assessment in rodents.
    Moscardo E; Maurin A; Dorigatti R; Champeroux P; Richard S
    J Pharmacol Toxicol Methods; 2007; 56(2):239-55. PubMed ID: 17629504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative.
    Ewart L; Aylott M; Deurinck M; Engwall M; Gallacher DJ; Geys H; Jarvis P; Ju H; Leishman D; Leong L; McMahon N; Mead A; Milliken P; Suter W; Teisman A; Van Ammel K; Vargas HM; Wallis R; Valentin JP
    Toxicol Sci; 2014 Dec; 142(2):427-35. PubMed ID: 25246669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary observation (Irwin) test in rodents for assessing acute toxicity of a test agent and its effects on behavior and physiological function.
    Roux S; Sablé E; Porsolt RD
    Curr Protoc Pharmacol; 2005 Jan; Chapter 10():Unit 10.10. PubMed ID: 22294127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target organ toxicities in studies conducted to support first time in man dosing: an analysis across species and therapy areas.
    Horner S; Ryan D; Robinson S; Callander R; Stamp K; Roberts RA
    Regul Toxicol Pharmacol; 2013 Apr; 65(3):334-43. PubMed ID: 23422911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions.
    Ewart L; Milne A; Adkins D; Benjamin A; Bialecki R; Chen Y; Ericsson AC; Gardner S; Grant C; Lengel D; Lindgren S; Lowing S; Marks L; Moors J; Oldman K; Pietras M; Prior H; Punton J; Redfern WS; Salmond R; Skinner M; Some M; Stanton A; Swedberg M; Finch J; Valentin JP
    J Pharmacol Toxicol Methods; 2013; 68(1):30-43. PubMed ID: 23665080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability of non-clinical behavioral CNS safety assessment: An intercompany comparison.
    Himmel HM; ; Delaunois A; Deurinck M; Dinklo T; Eriksson Faelker TM; Habermann C; Heers C; Hempel K; Lorenz H; Rosch A; Schauerte H; Teuns G; Traebert M; van Amsterdam C; van der Linde H
    J Pharmacol Toxicol Methods; 2019; 99():106571. PubMed ID: 30928509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are adverse events of nevirapine and efavirenz related to plasma concentrations?
    Kappelhoff BS; van Leth F; Robinson PA; MacGregor TR; Baraldi E; Montella F; Uip DE; Thompson MA; Russell DB; Lange JM; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(4):489-98. PubMed ID: 16038474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A functional observational battery for use in canine toxicity studies: development and validation.
    Gad SC; Gad SE
    Int J Toxicol; 2003; 22(6):415-22. PubMed ID: 14680988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spectrum of effects detected in the rat functional observational battery following oral administration of non-CNS targeted compounds.
    Redfern WS; Strang I; Storey S; Heys C; Barnard C; Lawton K; Hammond TG; Valentin JP
    J Pharmacol Toxicol Methods; 2005; 52(1):77-82. PubMed ID: 15936219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.